Antares Pharma, Inc. (ATRS)
(Delayed Data from NSDQ)
$3.04 USD
+0.06 (2.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.04 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ATRS]
Reports for Purchase
Showing records 1 - 20 ( 49 total )
Industry: Medical - Dental Supplies
Takeout by Drug-Delivery Player Halozyme; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
4Q21 and 2022 Guidance Ahead of Estimates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Model Update Ahead of 2022 First-Time Guidance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
Gx Forteo Delay and Increased Spend Brings Nerves about 2022; Tlando is Accretive, But Risk Discount Lowers Our PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
2Q21: Solid Beat Despite One-time Drags, Sets Up Strong 2H; Looking for Gx Forteo and AR-1902 Clarity
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
1Q21: EpiPen Blowing the Doors Off; Raise Gx Forteo Royalties and Target to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
3Q20: Xyosted and EpiPen Continue to Drive Ship; Street Nocdurna Expectations are Low; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Multiple Sclerosis Therapy Demonstrates Early Signs of Durability
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Dental Supplies
Small Nocdurna Tuck-in Acquisition to Leverage the Successful Xyosted Salesforce; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
2Q20: Steady Grower Xyosted Drives Another Beat; Pre-COVID Guidance Reinstated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
Industry: Medical - Dental Supplies
4Q19: Continuing the Hot Beat Streak; 2020 Set for First Full-Year Profitability; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Adjusting Numbers Following Partner Updates; Lower 2020 Royalties, But Long-Term Growth Unchanged; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
3Q19 Results: Another Beat and Revenue Guidance Bump; First Ever Profit, Raise Target to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
2Q19: Another Solid Beat, Including Xyosted; We Still See 4Q Breakeven; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
1Q19 Results; Strength Across the Portfolio; Xyosted Solid Rx out of the Gates; Still See 4Q Breakeven
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Industry: Medical - Dental Supplies
Makena Anxiety Likely Overblown; Updating Estimates Post 4Q18; We See a Back-Weighted 2019; Breakeven in 4Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O